The takeaway
Immix Biopharma Inc shows a pronounced seasonal pattern over 5 years of data — strongest in November (+29.7%) and softest in February (−19.7%).
Right now
In July, the stock has fallen 25% of years, averaging −3.8%, roughly 5.9 pts behind the S&P 500.
The full picture
Immix Biopharma Inc's most dependable month has been November, higher in 4 of 4 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | — | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+32.4 pts); it has trailed the market most in February (−19.5 pts).
“vs S&P” is Immix Biopharma Inc’s average for a month minus the S&P 500’s average for that same month — isolating Immix Biopharma Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 4 years, November has closed higher 100% of the time versus 100% across the last 5 years — the pattern is holding.
Figures are the typical (median) November return and how often it rose — the last 4 years versus the last 5(the heatmap’s default window). This verdict stays anchored to that 5-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: November, up in all 4 Novembers while the other eleven tend to blur together.
Its average (+29.7%) and median (+24.7%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even November ranges by 15.6% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: November has cleared the S&P 500 by +27.3 points above the index. That consistency sets it apart from the field, where the average stock manages November only about 62% of the time.
A few other months pull their weight: June and December have also closed higher more often than not. On the other side of the ledger, February has been the soft spot — the weakest of 7 months that average a loss (−19.7%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, January, and August. Its roughest month on record was a −44.4% April in 2022 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: November aside, the stock's months offer little reliable tilt. With a short 5-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (November), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2021 its best month (November, +29.7%) has run well ahead of its worst (February, −19.7%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +29.7% and closing higher in all 4 years on record since 2021.
It's the weakest, averaging −19.7% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade